29-04-2024
|
|
|
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 29, 2024, titled "Glenmark Pharmaceuticals receives ANDA approval forAcetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)". |
|
|
|
25-04-2024
|
|
|
Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating |
|
|
|
12-04-2024
|
|
|
Glenmark Pharmaceuticals Limitedï¿‚ï¾ has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaï¿‚ï¾ (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. |
|
|
|
02-04-2024
|
|
|
GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
|
|
|
02-04-2024
|
|
|
Glenmark Pharmaceuticals Limited has informed the Exchange about Retirement |
|
|
|
21-03-2024
|
|
|
Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating |
|
|
|
14-03-2024
|
|
|
Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating |
|
|
|
13-03-2024
|
|
|
Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating |
|
|
|
13-03-2024
|
|
|
Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015'. |
|
|
|
12-03-2024
|
|
|
Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015'. |
|
|
|
|
|